John Russell Erickson

US Patent:

6613764, Sep 2, 2003

Filed:

Sep 28, 2001

Appl. No.:

09/868775

Inventors:

Ramnarayan S. Randad - Frederick MD
John W. Erickson - Frederick MD
Michael A. Eissenstat - Frederick MD
Lucyna Lubkowska - Frederick MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 315377

US Classification:

5142358, 514256, 514318, 544123, 544129, 544316

Abstract:

The present invention provides a compound of formula (I) wherein a, b, c, d, and e, are R , OR , SR , NR R , NHCOR , CO R , CN, NO , NH , N , or a halogen. R and R are H or alkyl, R and R are H or alkyl, and R is a non-aromatic substituent. Substituent A is OH, NH , or SH. Substituents B and B include amide and sulfonamide groups, which can be cyclic, acyclic, or amino acid derivatives. Alternatively, B and Râ together with the nitrogen to which they are bonded, and/or Bâ and R together with the nitrogen to which they are bonded, define a heterocycle. The present invention further provides a pharmaceutical composition that includes a carrier and a therapeutically effective amount of at least one compound of the present invention. The present invention further provides therapeutic methods that include administering a therapeutically effective amount of at least one compound of the present invention.

US Patent:

6649651, Nov 18, 2003

Filed:

Dec 23, 2002

Appl. No.:

10/089991

Inventors:

Piet T. B. P. Wigerinck - Vosselaar, BE
Guangyang Wang - Gaihersburg MD
Michael Eissenstat - Frederick MD
John W. Erickson - Frederick MD

Assignee:

Tibotec Pharmaceuticals LTD

International Classification:

A61K 3136

US Classification:

514464, 549435

Abstract:

Novel bis-tetrahydrofuran benzodioxolyl sulfonamide compounds which are surprisingly effective protease inhibitors. The invention also relates to pharmaceutical compositions, methods of inhibiting retrovirus proteases, in particular multidrug resistant retrovirus proteases, methods of treating or combating infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication.

US Patent:

7087373, Aug 8, 2006

Filed:

Jun 5, 2002

Appl. No.:

10/161613

Inventors:

Dong Xie - Germantown MD, US
Wei Cao - Centereach NY, US
John W. Erickson - Frederick MD, US

Assignee:

Tibotec Pharmaceuticals Ltd. - County Cork

International Classification:

C12Q 1/37
G01N 33/53
G01N 33/48

US Classification:

435 4, 435 71, 435 23, 702 19

Abstract:

Methods for isothermal titration calorimetry analysis of the binding affinity of protease inhibitors to plasma proteins. A method that can quantitatively calculate free drug concentrations of protease inhibitors in human plasma, as well as a method to calculate therapeutic amounts and dosage regimens. Furthermore, the present invention provides a method that can calculate the effect of plasma proteins on the antiviral activity (EC50 values) of protease inhibitors from their binding affinities to plasma proteins. The present invention provides as well a method that can evaluate the in vivo anti-HIV efficacy of PIs in human plasma.

US Patent:

7109230, Sep 19, 2006

Filed:

Jan 7, 2003

Appl. No.:

10/337349

Inventors:

John W. Erickson - Frederick MD, US
Michael Eissenstat - Frederick MD, US
Abelardo Silva - Columbia MD, US
Sergei Gulnik - Frederick MD, US

Assignee:

Sequoia Pharmaceuticals, Inc. - Gaithersburg MD

International Classification:

A61K 31/40
C07D 209/36

US Classification:

514412, 548484

Abstract:

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

US Patent:

7132420, Nov 7, 2006

Filed:

Jun 11, 2003

Appl. No.:

10/458873

Inventors:

Ramnarayan S. Randad - Frederick MD, US
John W. Erickson - Frederick MD, US
Michael A. Eissenstat - Frederick MD, US
Lucyna Lubkowska - Frederick MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 31/5375
A61K 31/505
C07D 413/12
C07D 239/04

US Classification:

5142355, 544106, 544111, 544224, 544242, 5462681, 5462821, 5142312, 514256, 514336, 514340

Abstract:

The present invention provides an aspartic proteinase-inhibiting compound of the formula:Further provided are pharmaceutical compositions, which include a therapeutically effective amount of at least one of the foregoing compounds, and therapeutic methods of using the foregoing compounds.

US Patent:

7151163, Dec 19, 2006

Filed:

Apr 28, 2004

Appl. No.:

10/833304

Inventors:

John W. Erickson - Potomac MD, US
Abelardo Silva - Ellicott City MD, US

Assignee:

Sequoia Pharmaceuticals, Inc. - Gaithersburg MD

International Classification:

C07K 14/165
C07K 17/00
A61K 39/215
A61K 39/385

US Classification:

530363, 514 12, 4241861, 42419611, 4242211, 4241921

Abstract:

The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.

US Patent:

7157495, Jan 2, 2007

Filed:

Jun 25, 2003

Appl. No.:

10/606342

Inventors:

Guangyang Wang - Gaihersburg MD, US
Michael Eissenstat - Frederick MD, US
John W. Erickson - Frederick MD, US
Piet T. B. P. Wigerinck - Vosselaar, BE

Assignee:

Tibotec Pharmaceuticals, Ltd. - Co Cork
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 31/35

US Classification:

514464, 514465

Abstract:

Compositions comprising bis-tetrahydrofuran benzodioxyolyl sulfonamide compounds that are surprisingly effective protease inhibitors and a second antiretroviral compound are disclosed. Methods of inhibiting retrovirus proteases, in particular multi-drug resistant retrovirus proteases, methods of treating or preventing infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication are also disclosed.

US Patent:

7285566, Oct 23, 2007

Filed:

Jan 7, 2003

Appl. No.:

10/500888

Inventors:

John W. Erickson - Potomac MD, US
Michael Eissenstat - Frederick MD, US
Abelardo Silva - Ellicott City MD, US
Sergei Gulnik - Frederick MD, US

International Classification:

A61K 31/404
C07D 209/30

US Classification:

514367, 514375, 548159, 548222

Abstract:

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.